Research programme: anti-CD155 antibodies - Biotecnol

Drug Profile

Research programme: anti-CD155 antibodies - Biotecnol

Latest Information Update: 14 Jun 2012

Price : $50

At a glance

  • Originator Biotecnol SA
  • Class Antibodies
  • Mechanism of Action CD antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 15 Nov 2007 Preclinical trials in Solid tumours in Portugal (Parenteral)
  • 15 Nov 2007 The anti-CD155 antibody programme is available for licensing worldwide (http://www.biotecnol.com/default.aspx?classification=00003201:00000001)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top